1. A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study
- Author
-
Javier A. Menendez, Samiha Saidani, Sara Verdura, Elisabet Cuyàs, Joan Dorca, Gemma Viñas, Agostina Stradella, Jose Perez-Garcia, Antonio Segura-Carretero, Idoia Morilla, Margarita Garcia, M. Luque, Kepa Amillano, Isabel Alvarez, Maria Buxó, Severina Domínguez, Susana Martínez, Neus Bosch, Begoña Martin-Castillo, Sonia Pernas, Javier Cortes, César A Rodríguez-Sánchez, Elsa Pérez, Eugeni López-Bonet, N. Batista-López, Álvaro Fernández-Ochoa, Jorge Joven, and Salvador Fernández-Arroyo
- Subjects
0301 basic medicine ,medicine.medical_specialty ,combinations ,Population ,Mama -- Càncer -- Tractament ,News ,Neutropenia ,Gastroenterology ,Càncer de mama ,resistance ,03 medical and health sciences ,breast cancer ,Breast cancer ,0302 clinical medicine ,Trastuzumab ,HER2 ,Internal medicine ,Quimioteràpia ,medicine ,Clinical endpoint ,cancer ,Chemotherapy ,Metformina ,education ,therapy ,education.field_of_study ,Breast -- Cancer -- Treatment ,business.industry ,medicine.disease ,Metformin ,trastuzumab ,Regimen ,030104 developmental biology ,Oncology ,Tolerability ,030220 oncology & carcinogenesis ,metformin ,business ,Research Paper ,medicine.drug - Abstract
The METTEN study assessed the efficacy, tolerability, and safety of adding metformin to neoadjuvant chemotherapy plus trastuzumab in early HER2-positive breast cancer (BC). Women with primary, non-metastatic HER2-positive BC were randomized (1:1) to receive metformin (850 mg twice-daily) for 24 weeks concurrently with 12 cycles of weekly paclitaxel plus trastuzumab, followed by four cycles of 3-weekly FE75C plus trastuzumab (arm A), or equivalent regimen without metformin (arm B), followed by surgery. Primary endpoint was the rate of pathological complete response (pCR) in the per-protocol efficacy population. pCR rate was numerically higher in the metformin-containing arm A (19 of 29 patients [65.5%, 95% CI: 47.3–80.1]) than in arm B (17 of 29 patients [58.6%, 95% CI: 40.7–74.5]; OR 1.34 [95% CI: 0.46–3.89], P = 0.589). The rate of breast-conserving surgery was 79.3% and 58.6% in arm A and B (P = 0.089), respectively. Blood metformin concentrations (6.2 μmol/L, 95% CI: 3.6–8.8) were within the therapeutic range. Seventy-six percent of patients completed the metformin-containing regimen; 13% of patients in arm A dropped out because of metformin-related gastrointestinal symptoms. The most common adverse events (AEs) of grade ≥3 were neutropenia in both arms and diarrhea in arm A. None of the serious AEs was deemed to be metformin-related. Addition of anti-diabetic doses of metformin to a complex neoadjuvant regimen was well tolerated and safe. Because the study was underpowered relative to its primary endpoint, the efficacy data should be interpreted with caution.
- Published
- 2018